Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis

Abstract

Background Infants born preterm compared with infants born at term are at an increased risk of dying and of serious morbidities in early life, and those who survive have higher rates of neurological impairments. It remains unclear whether exposure to repeat courses of prenatal corticosteroids can reduce these risks. This individual participant data (IPD) meta-analysis (MA) assessed whether repeat prenatal corticosteroid treatment given to women at ongoing risk of preterm birth in order to benefit their infants is modified by participant or treatment factors. Methods and findings Trials were eligible for inclusion if they randomised women considered at risk of preterm birth who had already received an initial, single course of prenatal corticosteroid seven or more days previously and in which corticosteroids were compared with either placebo or no placebo. The primary outcomes for the infants were serious outcome, use of respiratory support, and birth weight z-scores; for the children, they were death or any neurosensory disability; and for the women, maternal sepsis. Studies were identified using the Cochrane Pregnancy and Childbirth search strategy. Date of last search was 20 January 2015. IPD were sought from investigators with eligible trials. Risk of bias was assessed using criteria from the Cochrane Collaboration. IPD were analysed using a one-stage approach. Eleven trials, conducted between 2002 and 2010, were identified as eligible, with five trials being from the United States, two from Canada, and one each from Australia and New Zealand, Finland, India, and the United Kingdom. All 11 trials were included, with 4,857 women and 5,915 infants contributing data. The mean gestational age at trial entry for the trials was between 27.4 weeks and 30.2 weeks. There was no significant difference in the proportion of infants with a serious outcome (relative risk [RR] 0.92, 95% confidence interval [CI] 0.82 to 1.04, 5,893 infants, 11 trials, p = 0.33 for heterogeneity). There was a reduction in the use of respiratory support in infants exposed to repeat prenatal corticosteroids compared with infants not exposed (RR 0.91, 95% CI 0.85 to 0.97, 5,791 infants, 10 trials, p = 0.64 for heterogeneity). The number needed to treat (NNT) to benefit was 21 (95% CI 14 to 41) women/fetus to prevent one infant from needing respiratory support. Birth weight z-scores were lower in the repeat corticosteroid group (mean difference −0.12, 95%CI −0.18 to −0.06, 5,902 infants, 11 trials, p = 0.80 for heterogeneity). No statistically significant differences were seen for any of the primary outcomes for the child (death or any neurosensory disability) or for the woman (maternal sepsis). The treatment effect varied little by reason the woman was considered to be at risk of preterm birth, the number of fetuses in utero, the gestational age when first trial treatment course was given, or the time prio...

Targeting the Stress System During Gestation: Is Early Handling a Protective Strategy for the Offspring?

“…This issue is particularly relevant due to the common practice of multiple administrations of glucocorticoids to pregnant women during late gestation to ensure the survival of the preterm newborns. Even though synthetic glucocorticoids, such as dexamethasone (DEX) or betamethasone, have been extensively used rather than cortisol or hydrocortisone (Jobe, 2003;Oliveira et al, 2006;Singh et al, 2012), the natural glucocorticoid is increasingly considered as an alternative therapy during pregnancy (Crowther et al, 2019). Therefore, a long-term follow-up in children who were treated in utero with glucocorticoids is strongly recommended.…”

A rapid desensitization protocol in a case of drotaverine‑induced serum sickness-like reaction in a pregnant woman: A case report

“…For IgE-mediated reactions skin prick tests or intradermal tests are used for confirming the diagnosis, but for serum sickness-like reactions there are no available tests. Considering our patient was pregnant we did not perform a drug provocation test (7).…”

“…We used low doses of systemic corticosteroids as premedication in order to induce tolerance. The reason for using a low dose corticosteroid was the pregnancy (7).…”

Controversies in antenatal corticosteroid treatment

“…The Cochrane review which included 4733 women and 5700 babies from 10 trials showed a significant improvement in respiratory distress syndrome (RR: 0.83, 95% CI: 0.75‐0.91) and serious infant outcome (RR: 0.84, 95% CI: 0.75‐0.94) but a significant decrease in mean birth weight which was no longer significant when adjusted for gestational age . A recent individual participant meta‐analysis which included 11 randomized trials involving 4857 women and 5915 infants reported a significant decrease in the use of respiratory support (RR: 0.91, 95% CI: 0.85‐0.97) but also a significant decrease in birthweight in the group exposed to repeat prenatal steroids (mean difference: −0.12, 95% CI: −0.18 to −0.06) . No differences were seen in composite serious outcome for child or woman …”

“…A recent individual participant meta‐analysis which included 11 randomized trials involving 4857 women and 5915 infants reported a significant decrease in the use of respiratory support (RR: 0.91, 95% CI: 0.85‐0.97) but also a significant decrease in birthweight in the group exposed to repeat prenatal steroids (mean difference: −0.12, 95% CI: −0.18 to −0.06) . No differences were seen in composite serious outcome for child or woman …”